In a startling investigation, CNN has learned that the maker of a drug designed to treat an uncommon condition is increasingly pushing it on nursing home residents with dementia and Alzheimer’s — with sometimes dire consequences.
The U.S. Food and Drug Administration (FDA) approved Avanir Pharmaceuticals’ drug Nuedexta in 2010 for pseudobulbar affect, or PBA, a condition marked by bouts of uncontrollable crying or laughing.